Business Wire

OLYMPUS

Share
Olympus Launches VISERA ELITE III Surgical Visualization Platform

Olympus Corporation (“Olympus” - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the launch of VISERA ELITE III, its newest surgical visualization platform that addresses the needs of healthcare professionals (HCPs) for endoscopic procedures across multiple medical disciplines. VISERA ELITE III offers various imaging functions, all supported in one system enabling minimally invasive therapies such as Laparoscopic Colectomy and Laparoscopic Cholecystectomy. Future software upgrades will advance surgical imaging technology and allow for individual configurations that facilitate seamless support of various surgical applications leading to a reduction in investment costs. VISERA ELITE III will be available in Europe, Middle East and Africa (EMEA), parts of Asia, Oceania, and Japan in September 2022 or later.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005632/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Surgical visualization platform VISERA ELITE III (Photo: Business Wire)

“With VISERA ELITE III, we provide a best-in-class surgical visualization platform designed for multiple medical specialties and configurations, allowing HCPs to fully focus on the patient during surgery. By incorporating the technologies of its predecessors VISERA ELITE II and VISERA 4K UHD into one platform, VISERA ELITE III enhances the quality of endoscopic surgery, contributes to improved efficiency in the operating room, and hereby elevates the standard of care,” said Kanichi Matsumoto, Global Head of Surgical Endoscopy at Olympus.

One System for All

VISERA ELITE III system integrates the 3D and infrared1 imaging functions from VISERA ELITE II, and the 4K imaging function from VISERA 4K UHD system. It also supports fluorescence guided surgery as well as NBI2, a unique observation mode developed by Olympus. By providing surgeons with multiple observation modes, the all-in-one system supports standardization and increases efficiency in the operating room. Users can also set up customized departmental profiles on VISERA ELITE III for different medical disciplines such as general surgery, urology, gynecology, ENT surgery and more. The platform is compatible with existing endoscopes from VISERA ELITE II.

Innovation That Grows with Need

The platform allows software upgrades to add new surgical imaging functions as needed. Switching entire surgical visualization systems to access the latest technology is no longer necessary, which not only sets a new standard and provides a high degree of flexibility, but also makes VISERA ELITE III a future-proof investment.

Improved Image Quality for More Focus

VISERA ELITE III system comes with a focus adjust mode during 4K surgical observation and is equipped with the EDOF (Extended Depth of Field) function that allows precise endoscopic observations through continuous broad focus and seamless magnification. In addition, it provides the C-AF (Continuous Auto Focus) capability that automatically adjusts focus in accordance with the movement of the camera head and endoscope. This facilitates clearer image capture, both up close and at a greater distance, so that HCPs experience less stress during surgery, allowing them to concentrate on the patient and the procedure's outcome.

VISERA ELITE III combines Sony Corporation’s state-of-the-art digital imaging technologies with the expertise and experience in medical product development that Olympus has accumulated over decades as a leading endoscope manufacturer and addresses the growing needs of hospitals as recognized through extensive exchange with customers.

In developing VISERA ELITE III, Sony Olympus Medical Solutions, a joint venture company of Sony and Olympus, optimized each technology and image processing function specifically for medical applications to create the most advanced, open, and versatile surgical visualization platform Olympus has ever brought to market.

About Olympus

Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety.

In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, as well as customer solutions and medical services. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

______________________________
1 Infrared imaging is a special light observation function for observing the fluorescence generated by administering a fluorescent agent called indocyanine green (ICG) and by applying near-infrared light (light with a wavelength of 700-780 nm).
2 NBI (Narrow Band Imaging) is an imaging technique for examining features such as the small blood vessels in mucosa and the surface patterns. NBI highlights tissue by illuminating it with two narrow bands (wavelengths) of light that are absorbed by the hemoglobin in blood.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005632/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye